Skip to content

Replimune Group REPL Total Revenue

Discontinued — last reported Q3 '19

Total Revenue at other companies

Amgen logo
AmgenAMGN
$8.62B+5.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3.61B+19.0%
Regenxbio logo
RegenxbioRGNX
$6.39M-92.8%
Immunome logo
ImmunomeIMNM
$0-100%
CG Oncology logo
CG OncologyCGON
$1.08M+1,983%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$44.21M+168%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$932.63M+25.4%
Enterprise value$887.18M+22.5%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Replimune Group’s 10-Q, filed February 14, 2019, on SEC EDGAR. View the filing →

Questions, answered.

What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.